Results from Breo Ellipta Clinical Trial in COPD Patients Presented by GSK
GlaxoSmithKline recently presented new data from two analyses of the SUMMIT trial, a study that evaluated the impact of Breo Ellipta (fluticasone furoate/vilanterol or FF/VI 100/25 mcg) on the survival of patients ... Read more